Insider

Elevance Health, Inc.

ELV Health Care · 2 analyses · 4 expectations tracked

Elevance Health reported $51.4B in revenue (+1.4% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 4 open management expectations for this company. 2 insider sales recorded. Next scheduled event: Dividend on December 18, 2026.

Mentioned in recent filings: Tariffs

What changed

Upcoming events

As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →

Company history

October 2026

Elevance Health, Inc.: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-21: Revenue (us-gaap:Revenues), quarter 2026-07-01 to 2026-09-30: 51,429,000,000 USD (51.4 billion; 51,429 million); same period a year earlier (2025-07-01 to 2025-09-30): 50,711,000,000 USD (50.7 billion; 50,711 million); change +1.4% Source
  • 2026-10-21: Revenue (us-gaap:Revenues), year to date 2026-01-01 to 2026-09-30: 152,084,000,000 USD (152.1 billion; 152,084 million); same period a year earlier (2025-01-01 to 2025-09-30): 149,378,000,000 USD (149.4 billion; 149,378 million); change +1.8% Source
  • 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 1,269,000,000 USD (1.3 billion; 1,269 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,295,000,000 USD (1.3 billion; 1,295 million); change -2% Source
  • 2026-10-21: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 5,118,000,000 USD (5.1 billion; 5,118 million); same period a year earlier (2025-01-01 to 2025-09-30): 6,890,000,000 USD (6.9 billion; 6,890 million); change -25.7% Source
  • 2026-10-21: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 1,365,000,000 USD (1.4 billion; 1,365 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,189,000,000 USD (1.2 billion; 1,189 million); change +14.8% Source
  • 2026-10-21: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 4,592,000,000 USD (4.6 billion; 4,592 million); same period a year earlier (2025-01-01 to 2025-09-30): 5,115,000,000 USD (5.1 billion; 5,115 million); change -10.2% Source
  • 2026-10-21: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 7,512,000,000 USD (7.5 billion; 7,512 million); same period a year earlier (2025-01-01 to 2025-09-30): 4,206,000,000 USD (4.2 billion; 4,206 million); change +78.6% Source
  • 2026-10-21: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 789,000,000 USD (789 million); same period a year earlier (2025-01-01 to 2025-09-30): 823,000,000 USD (823 million); change -4.1% Source
  • 2026-10-21: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 10,348,000,000 USD (10.3 billion; 10,348 million); previous balance (2025-12-31): 9,491,000,000 USD (9.5 billion; 9,491 million); change +9% Source
  • 2026-10-21: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 83,007,000,000 USD (83 billion; 83,007 million); previous balance (2025-12-31): 77,468,000,000 USD (77.5 billion; 77,468 million); change +7.2% Source
  • 2026-10-21: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 44,681,000,000 USD (44.7 billion; 44,681 million); previous balance (2025-12-31): 43,882,000,000 USD (43.9 billion; 43,882 million); change +1.8% Source
  • 2026-10-21: Long-term debt (us-gaap:LongTermDebtNoncurrent), as of 2026-09-30: 30,382,000,000 USD (30.4 billion; 30,382 million); previous balance (2025-12-31): 30,797,000,000 USD (30.8 billion; 30,797 million); change -1.3% Source

July 2026

Elevance Health reported on medical membership, market-driven medical cost trends, and operational impacts of regulatory changes in its July 2026 filing.

  • As of June 30, 2026, Elevance Health served approximately 44.9 million medical members through its affiliated health plans. Source
  • The company reported that membership shifts from Medicaid to the Individual ACA business combined with lower effectuation rates have driven a market-wide increase in morbidity and elevated medical cost trends. Source
  • Medicaid cost trends remain elevated due to higher population acuity and increased utilization of services. Source
  • Elevance Health participated in the Public Exchange and expanded operations into Florida, Maryland, Texas, and Washington between 2025 and 2026. Source
  • CarelonRx continues to delegate certain pharmacy services to CVS Health Corporation's subsidiary CaremarkPCS Health, L.L.C. under an agreement through December 31, 2027. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 21, 2026. SEC

LatestEarlierChange
Revenue quarter$51.4B$50.7B+1.4%
Operating income quarter$1.3B$1.3B-2.0%
Net income quarter$1.4B$1.2B+14.8%
Diluted EPS quarter$6.27$5.32+17.9%
Operating cash flow year to date$7.5B$4.2B+78.6%
Cash and cash equivalents balance$10.3B$9.5B+9.0%
Long-term debt balance$30.4B$30.8B-1.3%

Next results expected around January 20, 2027 (estimate: the quarter ending about December 30, 2026 plus the 21 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

45.4Q4 '24*1.5%48.9Q1 '256.5%49.8Q2 '254.9%50.7Q3 '252.6%49.7Q4 '25*0.6%50.2Q1 '264.2%50.5Q2 '263.5%51.4Q3 '262.5%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Elevance Health, Inc. ELV$51.4B+1.4%2.5%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Johnson & Johnson JNJ$25.4B+5.9%—

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Company officers will reaffirm full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.

    Said November 10, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • Company officers will reaffirm the Company’s shareholders’ earnings guidance for full year 2026 to be at least $22.00 per diluted share, including approximately $7.00 per diluted share of net unfavorable items.

    Said November 10, 2026 · Period named: full year 2026 · Source · Our article

    Not yet checked against later reports.

  • Elevance Health expects FY 2026 adjusted diluted EPS of at least $29.00.

    Said October 21, 2026 · Period named: FY 2026 · Source · Our article

    Not yet checked against later reports.

  • The CEO expects at least 12% growth in adjusted diluted EPS in 2027 from a baseline of at least $26.75.

    Said October 21, 2026 · Period named: 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 5, 2026Ratnakar LavuSale notice filed1,300$440.00$572,000SEC
October 22, 2026Mark KayeSale notice filed10,584$440.13$4,658,357SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock19,523,886$7,591,277,244+2.8%Q3 2026
State Street10,493,831$4,080,211,369+0.6%Q3 2026
Wellington Management8,516,420$3,311,354,424-7.6%Q3 2026
Geode Capital Management5,216,506$2,019,246,207+1.0%Q3 2026
Norges Bank (Norway's sovereign fund)3,958,856$1,531,008,381—Q2 2026
Fidelity (FMR)2,370,165$921,567,674-24.3%Q3 2026
Citadel Advisors388,335$150,992,414-57.2%Q3 2026
Renaissance Technologies322,613$125,438,387+60.2%Q3 2026
Two Sigma Investments162,061$62,673,851+12,762.0%Q2 2026
D. E. Shaw & Co.150,631$58,568,346+7.3%Q3 2026
Capital Research Global Investors119,078$34,859,671—Q1 2026
Millennium Management3,926$1,526,507-99.5%Q3 2026
T. Rowe Price3,876,188$1,507,140-3.5%Q3 2026
Baupost Group (Seth Klarman)1,275,154$495,8050.0%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.